When large incumbents leave significant but challenging markets, leaner startups can leverage new technologies to drive change. As big pharmaceutical companies shy away from neurological disease research, Verge Genomics founder and CEO Alice Zhang describes how a confluence of technological advances in genomics is creating new opportunities. New nontraditional biotech companies, she observes, are being built by multidisciplinary teams fluent in both biology and computer science.
Related
Luke Sykora,
Stanford University
Starting Up in a Downturn
An Entrepreneurial Thought Leaders mini-guide for aspiring founders facing a troubled economy.
Josh Makower, MD,
Stanford Byers Center for Biodesign
The Biodesign Innovation Process [Entire Talk]
Innovation isn’t random – it’s a process that can be learned, improved, and effectively deployed to solve specific problems.
Josh Makower, MD,
Stanford Byers Center for Biodesign
The Biodesign Innovation Process [Entire Talk]
Innovation isn’t random – it’s a process that can be learned, improved, and effectively deployed to solve specific problems.
John Felts,
Cruz Foam
Engineering Green Materials [Entire Talk]
To scale a technology, engineers need to think beyond the technology itself.
John Felts,
Cruz Foam
Engineering Green Materials [Entire Talk]
To scale a technology, engineers need to think beyond the technology itself.
